ISOFOL — Isofol Medical AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK259.28m
- SEK144.45m
Brief: Isofol Medical Q2 Loss For Period Widens To SEK 54.0 Million
Brief: Isofol Announces Topline Results Of Phase III Agent Study
Brief: Isofol Receives Approval Of Biomarker Analysis Patent And Intention-To-Grant Patent Application For Study Dose Regimen In Europe
Brief: Isofol Receives Approval Of Biomarker Analysis Patent
Brief: Isofol Q1 Loss At SEK 47.9 Mln
Brief: Isofol Nomination Committee Proposes Jan Törnell As Chairman
Brief: Isofol Medical Q4 Loss For Period Widens To SEK 61.2 Mln
Brief: Isofol Medical AB Will Not Reach 300 PFS Events In Agent Study With Current Censoring Rules Based On FDA Decision
Brief: Isofol Medical AB Says Receives FDA Fast Track Designation For Arfolitixorin In Advanced Colorectal Cancer (MCRC)
Brief: Isofol Q3 Loss At SEK 51.0 Mln
Brief: Isofol Medical Intends To List Its Shares On Nasdaq Stockholm
Brief: Isofol Raises SEK 500 Million In Oversubscribed Rights Issue
Brief: Isofol Medical Plans Rights Issue Of About SEK 400 MLN
Brief: Isofol: Clinical Use Patent In Europe For Drug Candidate Arfolitixorin Will Be Approved
Brief: Isofol Receives Recommendation From iDSMB To Complete The Global Phase III Agent Study For Market Registration As Planned With 440 Patients
Brief: Isofol Q4 Net Loss Narrows To SEK 54.7 Million
Brief: Isofol Medical Presents Gene Expression Results From Completed Phase I/IIa ISO-CC-005 Study
Brief: Isofol Q3 Net Loss Narrows To SEK 30.1 Million
Brief: Isofol Announces Licensing Agreement For Paladin Labs